--- title: "Morning Trend | GIANT BIOGENE Bullish Confidence Wavers, Key Support at Risk?" description: "On January 27th, GIANT BIOGENE (2367.HK) experienced weak fluctuations during the trading session, repeatedly testing the support at the 28 yuan mark without success. Throughout the day, funds continu" type: "news" locale: "en" url: "https://longbridge.com/en/news/273814399.md" published_at: "2026-01-28T01:00:00.000Z" --- # Morning Trend | GIANT BIOGENE Bullish Confidence Wavers, Key Support at Risk? > On January 27th, GIANT BIOGENE (2367.HK) experienced weak fluctuations during the trading session, repeatedly testing the support at the 28 yuan mark without success. Throughout the day, funds continued to flow out, with a high proportion of trading occurring in the red, indicating a gradual loss of confidence among bulls, and the main positions began to loosen. The biotechnology sector has shown continued weakness over the past week due to differences in local policies. The sector's funds are extremely cautious, lacking leadership from major companies, making it difficult to ignite a bullish atmosphere in the short term. GIANT BIOGENE has not released any significant announcements recently, and the valuation support story struggles to attract new followers. The overall industry sentiment is low, with funds only able to switch between localized hotspots, leading to a further contraction in risk appetite. Technically, indicators such as MACD, KDJ, and RSI have all weakened, and a clear downward channel has formed on the daily chart. Although there have been occasional attempts by the main players to bottom-fish in the short term, there are no signs of an overall trend reversal, with the dominance of funds leaning more towards the bears. If there are active large orders that can reverse the trend in the intraday session, there may be a turning point; otherwise, the weak consolidation is likely to continue. In summary, GIANT BIOGENE is currently in a phase of dissipating bullish confidence. If the key support level of 28 yuan is breached, it may trigger a new round of technical sell-off. It is recommended that investors focus on position control, wait for unusual fund movements and intraday improvement signals, and avoid blindly betting on a rebound from the left side On January 27th, GIANT BIOGENE (2367.HK) experienced weak fluctuations during the trading session, repeatedly testing the support at the 28 yuan level without success. Throughout the day, funds continued to flow out, with a high proportion of trading occurring in the red, indicating that bullish confidence is gradually weakening, and the main positions are starting to loosen. The biotechnology sector has shown continued weakness over the past week due to differences in local policies. Funds in the sector are extremely cautious, lacking a leading company to drive momentum, making it difficult to ignite a bullish atmosphere in the short term. GIANT BIOGENE has not released any significant announcements recently, and the valuation support story struggles to attract new followers. The overall industry sentiment is low, with funds only able to switch between localized hotspots, leading to a further contraction in risk appetite. From a technical perspective, indicators such as MACD, KDJ, and RSI have all weakened, and a clear downward channel has formed on the daily chart. Although there have been occasional attempts by the main players to bottom-fish in the short term, there are no signs of an overall trend reversal, with control of funds leaning more towards the bears. If there are active large orders that can reverse the trend in the intraday session, there may be a turning point; otherwise, the weak consolidation is likely to continue. In summary, GIANT BIOGENE is currently in a phase of dissipating bullish confidence. If the key support level of 28 yuan is breached, it may trigger a new round of technical sell-off. It is recommended that investors focus on position control, wait for unusual fund movements and intraday improvement signals, and avoid blindly betting on a rebound from the left side ### Related Stocks - [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md) - [02367.HK - GIANT BIOGENE](https://longbridge.com/en/quote/02367.HK.md) - [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md) - [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md) - [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 石四藥 (2005) 發盈警料去年盈利倒退 45 至 60% | 石四藥集團發盈警，預期截至去年底止年度股東應佔溢利按年下跌 45 至 60%；2024 年度錄得股東應佔溢利 10.61 億港元。 | [Link](https://longbridge.com/en/news/276431030.md) | | 早盤趨勢｜鉅子生物多頭信心鬆動，關鍵支撐岌岌可危？ | 1 月 27 日，鉅子生物（2367.HK）盤中弱勢震盪，盤面反覆探底，多次試探 28 元整數關口支撐未果。全天資金持續流出，綠盤成交佔比高，顯示多頭信心逐步鬆動，主力持倉籌碼開始鬆懈。 生物科技板塊過去一週受地方政策分歧影響，持續表現低迷 | [Link](https://longbridge.com/en/news/273815223.md) | | 中國物流「雙面」進化論：從草莽江湖到存量博弈突圍｜陳新燊 | 中國物流行業經歷了從草莽創業到全球領先的轉變，年業務量在 2026 年突破 2,000 億件，成為世界第一。然而，行業面臨利潤低迷、高附加值瓶頸及國際市場受限等挑戰。儘管社會物流成本與 GDP 比率為 13.9%，與美日相比仍顯低效，但中國 | [Link](https://longbridge.com/en/news/276017585.md) | | 埃隆·馬斯克的 Neuralink 在中國激發了腦機接口技術的競賽 | Neuralink，由埃隆·馬斯克創立，正在推動中國腦機接口（BCI）發展的熱潮，像 NeuroXess 這樣的初創公司迅速進入人體試驗階段。NeuroXess 於 2021 年成立，已經在患者身上測試植入物。中國政府已將 BCI 列為戰略 | [Link](https://longbridge.com/en/news/276460367.md) | | 桌面技術人員因接受關於在奇怪地方紋身的教育而被判入獄 | 一名名叫卡爾的技術支持工作人員分享了他在 1990 年代初期在警察局監獄工作的經歷。在他第一次訪問時，他被介紹到監獄環境，並遇到了發表不當言論的囚犯。結果發現他的同事邁克開了個玩笑，把他引導到拘留室，作為對新員工的惡作劇。儘管感到震驚，卡爾 | [Link](https://longbridge.com/en/news/276421217.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.